These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4917 related articles for article (PubMed ID: 6302253)

  • 21. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
    Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
    Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity.
    Tang L; Duan R; Zhong YJ; Firestone RA; Hong YP; Li JG; Xin YC; Wu HL; Li Y
    Mol Cancer; 2014 Mar; 13():44. PubMed ID: 24588871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
    Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
    Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo.
    Tarasenko N; Cutts SM; Phillips DR; Berkovitch-Luria G; Bardugo-Nissim E; Weitman M; Nudelman A; Rephaeli A
    Biochem Pharmacol; 2014 Mar; 88(2):158-68. PubMed ID: 24463168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells.
    van Gisbergen MW; Cebula M; Zhang J; Ottosson-Wadlund A; Dubois L; Lambin P; Tew KD; Townsend DM; Haenen GR; Drittij-Reijnders MJ; Saneyoshi H; Araki M; Shishido Y; Ito Y; Arnér ES; Abe H; Morgenstern R; Johansson K
    Mol Pharm; 2016 Jun; 13(6):2010-25. PubMed ID: 27093577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and functional evaluation of a peptide derivative of 1-beta-D-arabinofuranosylcytosine.
    Balajthy Z; Aradi J; Kiss IT; Elödi P
    J Med Chem; 1992 Sep; 35(18):3344-9. PubMed ID: 1527783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.
    Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK
    Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms.
    Wu W; Luo Y; Sun C; Liu Y; Kuo P; Varga J; Xiang R; Reisfeld R; Janda KD; Edgington TS; Liu C
    Cancer Res; 2006 Jan; 66(2):970-80. PubMed ID: 16424032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug.
    Breistøl K; Hendriks HR; Fodstad O
    Eur J Cancer; 1999 Jul; 35(7):1143-9. PubMed ID: 10533461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy.
    de Graaf M; Nevalainen TJ; Scheeren HW; Pinedo HM; Haisma HJ; Boven E
    Biochem Pharmacol; 2004 Dec; 68(11):2273-81. PubMed ID: 15498517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymeric prodrug for release of an antitumoral agent by specific enzymes.
    Cavallaro G; Pitarresi G; Licciardi M; Giammona G
    Bioconjug Chem; 2001; 12(2):143-51. PubMed ID: 11312674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.
    Hu Z; Jiang X; Albright CF; Graciani N; Yue E; Zhang M; Zhang SY; Bruckner R; Diamond M; Dowling R; Rafalski M; Yeleswaram S; Trainor GL; Seitz SP; Han W
    Bioorg Med Chem Lett; 2010 Feb; 20(3):853-6. PubMed ID: 20060717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity.
    Fernandez AM; Van Derpoorten K; Dasnois L; Lebtahi K; Dubois V; Lobl TJ; Gangwar S; Oliyai C; Lewis ER; Shochat D; Trouet A
    J Med Chem; 2001 Oct; 44(22):3750-3. PubMed ID: 11606140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
    Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
    J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release.
    Zhan F; Chen W; Wang Z; Lu W; Cheng R; Deng C; Meng F; Liu H; Zhong Z
    Biomacromolecules; 2011 Oct; 12(10):3612-20. PubMed ID: 21905663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer.
    DiPaola RS; Rinehart J; Nemunaitis J; Ebbinghaus S; Rubin E; Capanna T; Ciardella M; Doyle-Lindrud S; Goodwin S; Fontaine M; Adams N; Williams A; Schwartz M; Winchell G; Wickersham K; Deutsch P; Yao SL
    J Clin Oncol; 2002 Apr; 20(7):1874-9. PubMed ID: 11919247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasminogen activator is an apparent lymphocyte mitogen.
    Cohen SD; Israel E; Spiess-Meier B; Wainberg MA
    J Immunol; 1981 Apr; 126(4):1415-20. PubMed ID: 6259259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
    Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
    Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell-binding moiety to caspase-3 activated doxorubicin prodrug.
    Cho YS; Chung SW; Kim HR; Won TH; Choi JU; Kim IS; Kim SY; Byun Y
    J Control Release; 2019 Feb; 296():241-249. PubMed ID: 30659905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 246.